Establishment Labs Holdings Inc. (NASDAQ: ESTA) (the “Company”), a medical technology company focused on Women’s Health – initially in the breast aesthetics and reconstruction market – today announced that it has commenced a public offering of approximately $55,000,000 of its common shares, to be sold by the Company in a registered public offering. The Company expects to grant the underwriters a 30-day option to purchase up to $8,250,000 of additional common shares. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The Company intends to use the net proceeds from this offering, together with its existing cash, to fund growth initiatives, including the expansion of its manufacturing facilities, market development activities related thereto, conduct or sponsor clinical studies and trials, and to provide for working capital and other general corporate purposes. The Company may also use a portion of the net proceeds from this offering to expand the sales force and operations, increase research and development activities, obtain regulatory approval to market and sell Motiva Implants in the United States and expand internationally.

Goldman Sachs & Co. LLC, Jefferies LLC, Cowen and Company, LLC, and UBS Investment Bank are acting as joint book-running managers for the offering. PJT Partners Inc. is serving as financial advisor to the Company in connection with the offering.